Baldwin to FDA: Maintain Public Trust in COVID-19 Vaccine Decisions by Making Reviews Transparent
"Full transparency throughout the review and authorization process is essential to countering real or perceived politicization and building public confidence in any approved vaccine."
WASHINGTON, D.C. – U.S. Senator Tammy Baldwin (D-WI), a member of the Senate Health, Education, Labor and Pensions (HELP) Committee, and her colleagues are calling on the U.S. Food and Drug Administration (FDA) to commit to full transparency in the COVID-19 vaccine review process amidst mounting political pressure from the President to approve a vaccine before Election Day. The lawmakers, led by Senators Elizabeth Warren (D-MA) and Maggie Hassan (D-NH), expressed concern that the Trump administration has overruled scientists and pressured federal agencies to approve products based on weak evidence,and they urged the FDA to ensure transparency in vaccine review efforts in order to maintain public trust.
“We write to seek your commitment that the Food and Drug Administration’s (FDA) review process for potential vaccinations against the coronavirus disease 2019 (COVID-19) will be fully transparent and accountable,” wrote the Senators. “We are encouraged by the development of a number of vaccine candidates, and we share the FDA’s goal of facilitating ‘the timely development of safe and effective vaccines to prevent COVID-19.’ However, we are concerned that the accelerated timeline and intense political pressure around the vaccine development process could have the unintended consequence of undermining public confidence in the safety and quality of an eventual vaccine.”
More than 100 vaccines against COVID-19 are currently in development worldwide, with 37 in human clinical trials proceeding at an unprecedented pace. To address public concerns that the rapid speed of vaccine development could compromise the integrity of the review process, the FDA issued guidelines in June 2020 to assist in the clinical development and licensure of vaccines for COVID-19. However, President Trump and his administration have continuously applied political pressure to the agency — including promising that a vaccine will be approved by the end of 2020, or even by Election Day. The Centers for Disease Control and Prevention (CDC) also recently notified states that they should be prepared to distribute a vaccine by November 1, further raising concerns that the approval process will be rushed. Such recent statements made by the Trump administration may risk undermining public confidence in the FDA unless the agency commits to greater transparency in the vaccine development and review process.
“In order to achieve broad acceptance with the public, a future vaccine for COVID-19 will need to overcome public skepticism about the speed of the process, underlying doubts about vaccine safety, long-standing mistrust of the medical system among communities of color – and the effects of the President’s ongoing political interference,”wrote the Senators. The Senators asked a series of questions, including whether meetings of the Vaccine and Related Biological Products Advisory Committee would be open to the public, if data and design details from clinical trials will be made available to the public, and how the FDA is involving representatives of communities of color, people with disabilities, older Americans, and other groups at elevated risk from COVID-19.
The letter was also signed by Senators Dianne Feinstein (D-CA), Kirsten Gillibrand (D-NY), Richard Blumenthal (D-CT), Tina Smith (D-MN), Jeffrey A. Merkley (D-OR), Angus S. King, Jr. (I-ME), Jack Reed (D-RI), Christopher S. Murphy (D-CT), Mazie K. Hirono (D-HI), Bernard Sanders (I-VT), Michael F. Bennet (D-CO), and Sherrod Brown (D-OH).
The Senators requested a response to their letter no later than September 28, 2020. The full letter is available here.
An online version of this release is available here.
- WI Daily: 308 New COVID-19 Cases - Urban Milwaukee - Mar 1st, 2021
- Wisconsin Anticipates First Shipment of Johnson & Johnson Vaccine - Wisconsin Department of Health Services - Mar 1st, 2021
- Marquette University announces in-person plans for fall 2021 semester - Marquette University - Mar 1st, 2021
- Dane County Drops Most Fines Against Dance Studio - Wisconsin Institute for Law & Liberty - Mar 1st, 2021
- Back in the News: Uline Workers Suffer Higher COVID-19 Rates - Bruce Murphy - Mar 1st, 2021
- Groups Now Eligible for the COVID-19 Vaccine - Wisconsin Department of Health Services - Mar 1st, 2021
- WI Daily: 464 New COVID-19 Cases - Urban Milwaukee - Feb 28th, 2021
- WI Daily: 689 New COVID-19 Cases - Urban Milwaukee - Feb 27th, 2021
- HDA Statement on FDA Authorization of Johnson & Johnson COVID-19 Vaccine - Healthcare Distribution Alliance - Feb 27th, 2021
- Gallagher Statement on Pelosi’s Payout - U.S. Rep Mike Gallagher - Feb 27th, 2021
Read more about Coronavirus Pandemic here
Mentioned in This Press Release
Recent Press Releases by U.S. Sen. Tammy Baldwin
Baldwin, Hoeven Introduce Bipartisan Legislation to Alleviate Feed Shortages for Farmers and RanchersFeb 24th, 2021 by U.S. Sen. Tammy Baldwin
Senators’ Bill Provides Flexibility for Haying and Grazing of Cover Crops
Bipartisan Commission Will Start Work on U.S. Attorneys and Federal Judgeship